iShares Nasdaq Biotechnology ETF (IBB)
112.04
+1.82 +1.65%
NASDAQ
Feb 15, 20:00
Delayed 2m
USD
IBB Key Stats
| Net Asset Value | Upgrade |
| Discount or Premium to NAV | Upgrade |
| Turnover Ratio | Upgrade |
| 1 Year Fund Level Flows | Upgrade |
View All IBB News
IBB News
-
WireHeadlineTime (ET)
-
MT Newswires02/15 13:36
-
SA Breaking News02/15 10:48
-
MT Newswires02/15 09:27
-
MT Newswires02/14 13:21
-
Yahoo02/14 13:00
-
MT Newswires02/14 09:25
-
MT Newswires02/13 13:42
-
MT Newswires02/13 09:27
-
Yahoo02/12 15:21
-
MT Newswires02/12 13:27
IBB Performance
| Total Return (Price) | Total Return (NAV) | Cat. Total Return (NAV) | % Rank in Cat. (NAV) | |
|---|---|---|---|---|
| 1M | 2.56% | 2.54% | 5.49% | 98 |
| 3M | 7.58% | 7.43% | 4.27% | 18 |
| 6M | -2.87% | -2.73% | -0.45% | 76 |
| YTD | 16.19% | 15.69% | 12.61% | 19 |
| 1Y | 1.33% | 1.28% | 7.41% | 81 |
| 3Y | 10.44% | 10.45% | 15.51% | 80 |
| 5Y | 5.66% | 5.63% | 9.81% | 84 |
| 10Y | 16.70% | 16.68% | 16.10% | 40 |
| 15Y | 10.37% | 10.39% | 10.49% | 51 |
| 20Y | -- | -- | 10.49% | -- |
IBB Asset Allocation
| Type | % Net | % Long | % Short |
|---|---|---|---|
| Cash | 0.10% | 0.10% | 0.00% |
| Stock | 99.90% | 99.90% | 0.00% |
| Bond | 0.00% | 0.00% | 0.00% |
| Convertible | 0.00% | 0.00% | 0.00% |
| Preferred | 0.00% | 0.00% | 0.00% |
| Other | 0.00% | 0.00% | 0.00% |
IBB Region Exposure
| Americas | 96.91% |
| North America | 96.91% |
| Latin America | 0.00% |
| Greater Europe | 2.42% |
| United Kingdom | 0.79% |
| Europe Developed | 1.52% |
| Europe Emerging | 0.00% |
| Africa/Middle East | 0.11% |
| Greater Asia | 0.67% |
| Japan | 0.00% |
| Australasia | 0.00% |
| Asia Developed | 0.16% |
| Asia Emerging | 0.50% |
| Market Classification | |
| % Developed Markets | 99.50% |
| % Emerging Markets | 0.50% |
IBB Stock Sector Exposure
| Basic Materials | 0.05% |
| Communication Services | 0.00% |
| Consumer Cyclical | 0.00% |
| Consumer Defensive | 0.00% |
| Energy | 0.00% |
| Financial Services | 0.00% |
| Healthcare | 99.95% |
| Industrials | 0.00% |
| Real Estate | 0.00% |
| Technology | 0.00% |
| Utilities | 0.00% |
IBB Stock Market Capitalization
| Giant | 14.56% |
| Large | 38.73% |
| Medium | 24.14% |
| Small | 18.23% |
| Micro | 4.33% |
IBB Stock Style Exposure
| Large Cap Value | 15.46% |
| Large Cap Blend | 16.84% |
| Large Cap Growth | 24.28% |
| Mid Cap Value | 2.31% |
| Mid Cap Blend | 2.81% |
| Mid Cap Growth | 18.38% |
| Small Cap Value | 1.68% |
| Small Cap Blend | 5.98% |
| Small Cap Growth | 12.26% |
View More Holdings
As of Feb. 14, 2019
IBB Top 10 Holdings
| Symbol | Name | % Weight | Price | % Chg |
|---|---|---|---|---|
| CELG | Celgene Corp | 8.06% | 90.69 | +0.01% |
| BIIB | Biogen Inc | 7.78% | 332.87 | +2.51% |
| GILD | Gilead Sciences Inc | 7.38% | 67.59 | +1.84% |
| AMGN | Amgen Inc | 7.17% | 188.34 | +0.89% |
| ILMN | Illumina Inc | 5.47% | 299.82 | +2.51% |
| REGN | Regeneron Pharmaceuticals Inc | 4.54% | 423.97 | +2.17% |
| VRTX | Vertex Pharmaceuticals Inc | 4.11% | 188.07 | +1.27% |
| ALXN | Alexion Pharmaceuticals Inc | 3.77% | 129.42 | +2.77% |
| INCY | Incyte Corp | 2.38% | 84.15 | +0.88% |
| BMRN | Biomarin Pharmaceutical Inc | 2.23% | 93.99 | +0.56% |
Advertisement
IBB One Page Reports
- One Page Report Download
IBB Basic Info
| Style | |
|---|---|
| Equity Style | Mid Cap/Growth |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Prospectus Objective | Specialty - Technology |
| Fund Owner Firm Name | iShares |
| Benchmark Index | |
|---|---|
NASDAQ Biotechnology TR USD |
100.0% |
IBB Manager Info
| Name | Tenure |
|---|---|
| Alan Mason | 2.80 yrs |
| Amy Whitelaw | 0.50 yrs |
| Diane Hsiung | 11.09 yrs |
| Greg Savage | 11.09 yrs |
| Jennifer Hsui | 6.50 yrs |
| Rachel Aguirre | 0.50 yrs |
IBB Net Fund Flows
| 1M | -281.41M |
| 3M | -434.82M |
| 6M | -846.29M |
| YTD | -281.41M |
| 1Y | -1.834B |
| 3Y | 248.58M |
| 5Y | 1.425B |
| 10Y | 2.112B |
IBB Risk Info
| Beta (5Y) | 1.505 |
| Max Drawdown (All) | 62.85% |
| Historical Sharpe (10Y) | 0.9131 |
| Historical Sortino (All) | 0.5636 |
| 30-Day Rolling Volatility | 23.62% |
| Daily Value at Risk (VaR) 1% (All) | 4.83% |
| Monthly Value at Risk (VaR) 1% (All) | 19.27% |
IBB Fundamentals
| Dividend Yield TTM (2-15-19) | 0.28% |
| 30-Day SEC Yield (4-30-18) | 0.13% |
| 7-Day SEC Yield | -- |
| Weighted Average PE Ratio | 24.43 |
| Weighted Average Price to Sales Ratio | 5.987 |
| Weighted Average Price to Book Ratio | 5.085 |
| Weighted Median ROE | 1.19% |
| Weighted Median ROA | -5.11% |
| Forecasted Dividend Yield | 0.52% |
| Forecasted PE Ratio | 14.20 |
| Forecasted Price to Sales Ratio | 4.117 |
| Forecasted Price to Book Ratio | 3.924 |
| Number of Holdings | 225 |
IBB Growth Estimates
| Forecasted 5 Yr Earnings Growth | 15.49% |
| Forecasted Book Value Growth | 6.70% |
| Forecasted Cash Flow Growth | 2.09% |
| Forecasted Earnings Growth | -10.62% |
| Forecasted Revenue Growth | 9.62% |
IBB Attributes
| Key Dates | |
|---|---|
| Inception Date | 2/5/2001 |
| Termination Date | |
| Last Annual Report Date | 3/31/2018 |
| Last Prospectus Date | 8/1/2018 |
| Attributes | |
| Exchange Traded Share | Yes |
| Exchange Traded Note | No |
| Enhanced Index Fund | No |
| Fixed Distribution Fund | No |
| High-Net Worth Individual Fund | No |
| Index Fund | Yes |
| Inverse Fund | No |
| Leveraged Fund | No |
| Fund of Funds | No |
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan | Yes |
| Socially Responsible Fund | No |
| General Availability | |
| Available for Insurance Product | No |
| Available for Retirement Plan | No |
| Available for RRSP | No |
IBB Excel Add-In Codes
- Name: =YCI("IBB","name")
- Broad Asset Class: =YCI("IBB", "broad_asset_class")
- Broad Category: =YCI("IBB", "broad_category_group")
- Prospectus Objective: =YCI("IBB", "prospectus_objective")
To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.
Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.
Advertisement
